Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 -1.10%18 EBITDA Margin % is 37.38% as of Mar. 2026, which is 5% below its 10-year median of 39.35. GuruFocus rates BOM:544619 with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Sudeep Pharma ranks better than 92.51% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sudeep Pharma's EBITDA for the
three
months ended in Mar. 2026 was ₹669 Mil. Sudeep Pharma's Revenue for the
three
months ended in Mar. 2026 was ₹1,789 Mil. Therefore, Sudeep Pharma's EBITDA margin for the quarter that ended in Mar. 2026 was 37.38%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sudeep Pharma EBITDA Margin % Related Terms
Sudeep Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudeep Pharma (BOM:544619) has a EBITDA Margin % of 37.38% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sudeep Pharma and its competitors. This is near median its historical median of 39.35. Over the past decade, Sudeep Pharma's EBITDA Margin % has ranged from 22.83 to 41.11. According to the industry distribution chart, Sudeep Pharma ranks #72 out of 961 companies in the Drug Manufacturers industry, placing it in the top 7.5%.
Is Sudeep Pharma's EBITDA Margin % too high?
Sudeep Pharma's current EBITDA Margin % of 37.38% is near median its 10-year median of 39.35. Over the past 10 years, this metric has ranged from a low of 22.83 to a high of 41.11. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Sudeep Pharma's value of 37.38% is 200.5% above this industry median. Based on the distribution chart, Sudeep Pharma ranks #72 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sudeep Pharma has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #72 out of 961 companies for EBITDA Margin %. This places Sudeep Pharma in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Sudeep Pharma's value of 37.38% is 200.5% above this benchmark. Historically, Sudeep Pharma's own EBITDA Margin % has ranged from 22.83 to 41.11 over the past decade. While the company's 10-year median is 39.35 vs. the industry median of 12.44, Sudeep Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudeep Pharma's current EBITDA Margin % of 37.38% is 200.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current EBITDA Margin % is 37.38%, which is near median its own 10-year median of 39.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current EBITDA Margin % of 37.38%. The current EBITDA Margin % is 37.38%, which is near median its 10-year median of 39.35 and 200.5% above the Drug Manufacturers industry median of 12.44. Sudeep Pharma's overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current EBITDA Margin % is 37.38% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
18GF Score
Get the complete analysis for BOM:544619
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
